Discovery and clinical introduction of first-in-class imipridone ONC201

ONC201 is the founding member of a novel class of anti-cancer compounds called imipridones that is currently in Phase II clinical trials in multiple advanced cancers. Since the discovery of ONC201 as a p53-independent inducer of TRAIL gene transcription, preclinical studies have determined that ONC2...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Allen, Joshua E., Kline, C. Leah B., Prabhu, Varun V., Wagner, Jessica, Ishizawa, Jo, Madhukar, Neel, Lev, Avital, Baumeister, Marie, Zhou, Lanlan, Lulla, Amriti, Stogniew, Martin, Schalop, Lee, Benes, Cyril, Kaufman, Howard L., Pottorf, Richard S., Nallaganchu, B. Rao, Olson, Gary L., Al-Mulla, Fahd, Duvic, Madeleine, Wu, Gen Sheng, Dicker, David T., Talekar, Mala K., Lim, Bora, Elemento, Olivier, Oster, Wolfgang, Bertino, Joseph, Flaherty, Keith, Wang, Michael L., Borthakur, Gautam, Andreeff, Michael, Stein, Mark, El-Deiry, Wafik S.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342060/
https://ncbi.nlm.nih.gov/pubmed/27602582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11814
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados